TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8926739

Group type: EXPERIMENTAL
Intervention: Cannabinoid immunoassays with 100‐ng/mL cutoff
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cannabinoid immunoassays with 50‐ng/mL cutoff
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cannabinoid immunoassays with 20‐ng/mL cutoff
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Gas chromatography‐mass spectrometry (GC‐MS)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Commercial cannabinoid immunoassay with a 50‐ng/mL cutoff
Number of subjects: 6
Study: 2031824

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with isobaric 0.5% bupivacaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with hyperbaric 0.5% bupivacaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Extradural anaesthesia with isobaric 0.5% bupivacaine
Number of subjects: 150
Study: 7017486

Group type: EXPERIMENTAL
Intervention: guacetisal (Broncaspin)
Number of subjects: 26

Group type: COMPARATOR
Intervention: bromexine
Number of subjects: 26
Study: 30564950

Group type: EXPERIMENTAL
Intervention: Echocardiographic follow-up at 6 months
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: History of chronic heart failure at baseline
Number of subjects: 219
Study: 28807915

Group type: COMPARATOR
Intervention: 14-day bismuth quadruple therapy
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 14-day hybrid therapy
Number of subjects: 330
Study: 26537161

Group type: EXPERIMENTAL
Intervention: ProDisc-C Total Disc Replacement
Number of subjects: 209

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 209
Study: 23572220

Group type: EXPERIMENTAL
Intervention: TEP
Number of subjects: 378

Group type: COMPARATOR
Intervention: LLA
Number of subjects: 378
Study: 22051126

Group type: EXPERIMENTAL
Intervention: Assisted search group (librarian assistance)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-assisted (control) group
Number of subjects: 18
Study: 19057518

Group type: EXPERIMENTAL
Intervention: Coadministered amlodipine 5 mg and atorvastatin 10 mg
Number of subjects: 668

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 668

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study: 17324005

Group type: EXPERIMENTAL
Intervention: Cinacalcet 30 mg twice daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15107654

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study: 11870141

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IvIg) treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combined data from IvIg treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Combined data from placebo treatment
Number of subjects: 58
Study: 9850901

Group type: EXPERIMENTAL
Intervention: MDX‐RA (investigational immunotoxin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7856293

Group type: EXPERIMENTAL
Intervention: 24-valent Klebsiella capsular polysaccharide vaccine and eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously
Number of subjects: 41

Group type: COMPARATOR
Intervention: 24-valent Klebsiella capsular polysaccharide vaccine and eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered 14 days apart
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both vaccination schedules
Number of subjects: 41
Study: 2791807

Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline/Placebo
Number of subjects: 41
Study: 1217683

Group type: EXPERIMENTAL
Intervention: Etidocaine 1% with adrenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline
Number of subjects: 0
Study: 31894414

Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Exercise + Protein (EP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 100
Study: 30187632

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/d, regular group (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/d, intermittent group (n = 25)
Number of subjects: 50
Study: 26757022

Group type: EXPERIMENTAL
Intervention: Cerebralcare Granule (CG)
Number of subjects: 3251

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3251
Study: 26215431

Group type: EXPERIMENTAL
Intervention: HEI plus fesoterodine
Number of subjects: 682

Group type: COMPARATOR
Intervention: fesoterodine alone (control)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 682
Study: 24135593

Group type: EXPERIMENTAL
Intervention: 750 µg of AFB1/kg diet (750 ppb of AFB1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 75 µg of AFB1/kg diet (75 ppb of AFB1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (no AFB1)
Number of subjects: 0
Study: 21458097

Group type: EXPERIMENTAL
Intervention: Liraglutide (once-daily injection for 16 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (normal glycemic subjects)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: T2DM (pre-treatment)
Number of subjects: 30
Study: 18358692

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS combined with pergolide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cathodal tDCS combined with placebo
Number of subjects: 12
Study: 16241018

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: General anesthesia via facemask (GA-M)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: General anesthesia via endotracheal intubation (GA-T)
Number of subjects: 260
Study: 12018920

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Omeprazole 40 mg
Number of subjects: 130
Study: 9665421

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1200 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7655766

Group type: EXPERIMENTAL
Intervention: Pranidipine (1‐2 mg) once daily for 1‐2 weeks
Number of subjects: 9
Study: 2816361

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1139128

Group type: EXPERIMENTAL
Intervention: Small doses of subcutaneous sodium heparin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study: 31862764

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 57
Study: 29773696

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) plus usual care (UC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 39
Study: 27230862

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) + Usual Care (UC) for 16 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual Care (UC) alone for 16 weeks
Number of subjects: 42
Study: 24809242

Group type: EXPERIMENTAL
Intervention: Add-on bitopertin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSFS
Number of subjects: 0
Study: 22825283

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional weaning
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 20

Group type: COMPARATOR
Intervention: NIV and Conventional weaning
Number of subjects: 20
Study: 20376479

Group type: EXPERIMENTAL
Intervention: Compression treatment (n = 8) - wore full leg compression stockings for 12 h after exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: Passive recovery (n = 9) - no intervention
Number of subjects: 17
Study: 17990102

Group type: EXPERIMENTAL
Intervention: Doxorubicin and paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxorubicin and docetaxel
Number of subjects: 0
Study: 15670888

Group type: EXPERIMENTAL
Intervention: dTpa formulation with 0.5 mg aluminium
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: dTpa formulation with 0.3 mg aluminium
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: dTpa formulation with 0.133 mg aluminium
Number of subjects: 647

Group type: COMPARATOR
Intervention: dTpa formulations with varying aluminium content
Number of subjects: 647
Study: 12572904

Group type: EXPERIMENTAL
Intervention: Consupren solution
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sandimmun Neoral solution
Number of subjects: 11
Study: 9672517

Group type: EXPERIMENTAL
Intervention: Ganglioside-supplemented formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control milk formula
Number of subjects: 0
Study: 8024135

Group type: EXPERIMENTAL
Intervention: isoflurane, nitrous oxide, and oxygen (12 patients)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: isoflurane, air, and oxygen (7 patients)
Number of subjects: 19
Study: 2691662

Group type: EXPERIMENTAL
Intervention: Modified precision attachment design
Number of subjects: 10

Group type: COMPARATOR
Intervention: Original prosthetic design
Number of subjects: 10
Study: 4566958

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (antrum innervated)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Selective vagotomy (antrum denervated)
Number of subjects: 40
Study: 30363038

Group type: EXPERIMENTAL
Intervention: Progressive Training Group (PTG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Constant Training Group (CTG)
Number of subjects: 21
Study: 31436447

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Patient Navigation with Contingency Management (PN + CM)
Number of subjects: 801
Study: 28148500

Group type: EXPERIMENTAL
Intervention: Calcium with vitamin D (1000 mg elemental Ca with 400 IU vitamin D3/d)
Number of subjects: 5823

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5823
Study: 25445634

Group type: EXPERIMENTAL
Intervention: Beetroot juice
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 24100635

Group type: EXPERIMENTAL
Intervention: Household water filters
Number of subjects: 0
Study: 21415458

Group type: EXPERIMENTAL
Intervention: Fear of dying (experimental group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dental anxiety (control group)
Number of subjects: 80
Study: 19348536

Group type: EXPERIMENTAL
Intervention: Face Inversion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upright Faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inverted Faces
Number of subjects: 0
Study: 17898366

Group type: EXPERIMENTAL
Intervention: Clevidipine (0.4-8.0 microg x kg(‐1) x min(‐1))
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo (20% lipid emulsion)
Number of subjects: 152
Study: 15281537

Group type: EXPERIMENTAL
Intervention: Leg wrapping with tight elastic bandages
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no leg wrapping)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 11529331

Group type: EXPERIMENTAL
Intervention: Excretory-secretory (ES) products of Gnathostoma spinigerum infective larvae
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatic extract of Gnathostoma spinigerum infective larvae
Number of subjects: 0

Group type: COMPARATOR
Intervention: Somatic antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Excretory-secretory (ES) antigen
Number of subjects: 0
Study: 9790450

Group type: EXPERIMENTAL
Intervention: Leukocyte interferon-alpha (LE-IFN-alpha) administered at a dose of 3 MU three times a week for six months (group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Leukocyte interferon-alpha (LE-IFN-alpha) administered at a dose of 3 MU three times a week for twelve months (group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Leukocyte interferon-alpha (LE-IFN-alpha)
Number of subjects: 24
Study: 8091119

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan in water-free propylene glycol (PG)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan with 1.5% SLS in PG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.15% triclosan in PG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.075% triclosan in PG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan in diluted PG (1:8 in water) with 1.5% SLS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan in 0.5% sodium carbonate
Number of subjects: 12

Group type: COMPARATOR
Intervention: water (negative control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine acetate (CHX) (positive control)
Number of subjects: 12
Study: 29462005

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation with gemcitabine (54 Gray external beam radiation) followed by surgery
Number of subjects: 110

Group type: COMPARATOR
Intervention: Upfront surgery followed by chemoradiation
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 110
Study: 27129425

Group type: EXPERIMENTAL
Intervention: Morning vaccination (9-11 am)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Afternoon vaccination (3-5 pm)
Number of subjects: 276
Study: 24090538

Group type: EXPERIMENTAL
Intervention: Nurse-administered educational intervention about MRSA prevention (brochure and tools for nurses)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nurse-administered educational intervention about MRSA prevention
Number of subjects: 61
Study: 22038174

Group type: EXPERIMENTAL
Intervention: 36 and 40 mm femoral head
Number of subjects: 184

Group type: COMPARATOR
Intervention: 32 mm femoral head
Number of subjects: 184
Study: 20386323

Group type: EXPERIMENTAL
Intervention: Feeding started at 3 hours after PEG placement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Feeding started at 6 hours after PEG placement
Number of subjects: 40
Study: 18435971

Group type: EXPERIMENTAL
Intervention: Amplatzer
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Helex
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: CardioSEAL-STARflex
Number of subjects: 660
Study: 16169869

Group type: EXPERIMENTAL
Intervention: Daily haemodialysis (DHD) for 8 weeks, six times/week, each session half the usual time
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Daily haemodialysis (DHD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional haemodialysis (CHD)
Number of subjects: 12
Study: 14690787

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10985320

Group type: EXPERIMENTAL
Intervention: Bimonthly home collection of oral fluid (OF) specimens
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Bimonthly home collection of dried blood spot (DBS) specimens
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Telephone results disclosure
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Bimonthly testing
Number of subjects: 241
Study: 8959286

Group type: EXPERIMENTAL
Intervention: High monoamine meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Caffeine (one caffeinated cola per hour)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nicotine (smoking one cigarette per hour)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lorazepam (2 mg IV push)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 10
Study: 19186418

Group type: EXPERIMENTAL
Intervention: Thermafil technique
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dentin plug
Number of subjects: 80

Group type: COMPARATOR
Intervention: Obtura technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ultrafil technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Touch 'n Heat technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (patent teeth)
Number of subjects: 80
Study: 3902203

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus cisplatin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 92
Study: 30548121

Group type: EXPERIMENTAL
Intervention: High-energy formula (HF) 100 kcal/100 mL for 7 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard formula 67 kcal/100 mL for 7 days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-energy formula (HF)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 64
Study: 29979610

Group type: EXPERIMENTAL
Intervention: Normal shoulder tackle
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low tackle
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Opposite-leg tackle
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low and opposite-leg tackle
Number of subjects: 13
Study: 27538259

Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Inactivated Influenza Vaccine (IIV)
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 1186

Group type: COMPARATOR
Intervention: IIV
Number of subjects: 1186

Group type: COMPARATOR
Intervention: LAIV vs IIV
Number of subjects: 1186
Study: 24633761

Group type: EXPERIMENTAL
Intervention: Mifepristone 300 mg daily for the first week, followed by 300 mg for the next 3 weeks, then discontinued with reassessment 8 weeks later.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo during the first week of treatment.
Number of subjects: 15
Study: 22899904

Group type: EXPERIMENTAL
Intervention: L. plantarum MF 1298 (10(10) CFU), once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20145228

Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 50
Study: 18090697

Group type: EXPERIMENTAL
Intervention: Continuation therapy with ECT
Number of subjects: 201

Group type: COMPARATOR
Intervention: Continuation therapy with medications
Number of subjects: 201
Study: 15958319

Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (40 ml in 250 ml 10% glucose and saline, once daily for 7 days)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Routine comprehensive therapy (control group)
Number of subjects: 85
Study: 12107635

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL)
Number of subjects: 107
Study: 9529179

Group type: EXPERIMENTAL
Intervention: Plaster immobilization for 1 week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plaster immobilization for 3 weeks
Number of subjects: 0
Study: 7876629

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 1875

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 1875

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 1875
Study: 2192634

Group type: EXPERIMENTAL
Intervention: Efamol (evening primrose oil) at a dose of 6 capsules daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (equivalent dose of capsules)
Number of subjects: 200
Study: 84895

Group type: EXPERIMENTAL
Intervention: Active immunisation with a clostridial toxoid prepared from type-C cultures
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2500
Study: 31377868

Group type: EXPERIMENTAL
Intervention: Tiszasüly hot mud pack
Number of subjects: 60

Group type: COMPARATOR
Intervention: Kolop hot mud pack
Number of subjects: 60
Study: 30817721

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (50 min of moderate-intensity, supervised aerobic exercise, three times per week)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 71
Study: 27709248

Group type: EXPERIMENTAL
Intervention: Two-injection digital nerve block technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single-injection digital nerve block technique
Number of subjects: 50
Study: 26184491

Group type: EXPERIMENTAL
Intervention: Colestilan (6-15 g/day)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 23738530

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive-Behavioural Therapy (TF-CBT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 50
Study: 21436148

Group type: EXPERIMENTAL
Intervention: NoLAC (lactose-free milk protein-based formula)
Number of subjects: 128

Group type: COMPARATOR
Intervention: LAC (standard commercial lactose-containing milk-based formula)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: NoLAC
Number of subjects: 128

Group type: COMPARATOR
Intervention: LAC
Number of subjects: 128
Study: 19863218

Group type: EXPERIMENTAL
Intervention: Axillary Lymph Edema (ALE)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Arm Pain
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Sensation of Heaviness
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Health-Related Quality of Life (HRQoL)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Predictive Factors for HRQoL
Number of subjects: 204
Study: 16924986

Group type: EXPERIMENTAL
Intervention: OptiBond FL (3-step etch-and-rinse adhesive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil SE (2-step self-etch adhesive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scotchbond 1 (2-step etch-and-rinse adhesive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adper Prompt (1-step self-etch adhesive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FujiBond LC (2-step resin-modified glass-ionomer adhesive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reactmer (1-step resin-modified glass-ionomer adhesive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-step etch-and-rinse adhesive (OptiBond FL)
Number of subjects: 0
Study: 15247162

Group type: EXPERIMENTAL
Intervention: Strength training (3 times/week for 12 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Electrical muscle stimulation (1 hour/day for 12 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard rehabilitation (1 hour/day for 12 weeks)
Number of subjects: 30